AIF-1 is an inflammatory cytokine influencing the immune system. There are increased levels of AIF-1 in the synovial fluid of patients with rheumatoid arthritis (RA). Sulfasalazine still remains the mainstay for the treatment of RA. It has an anti-inflammatory effect, inhibiting the action of inflammatory mediators. The aim of our study was to examine the association between AIF-1 (rs2269475:C>T, rs2736182:G>A, rs2259571:A>C) polymorphisms and response to sulfasalazine treatment in RA patients.
A total of 112 RA patients were enrolled in the study.
There were no statistically significant associations between AIF-1 polymorphisms and response to sulphasalazine treatment.
The results of this study suggest a lack of association between AIF-1 gene polymorphisms and response to sulphasalazine treatment.